Endra Life Sciences

Q1 FY2026 EarningsQ2 FY26 results were mixed relative to consensus, with a surprise net income beat driven entirely by non-operating digital asset gains. Revenue remained at zero in line with expectations as the TAEUS platform awaits FDA approval. GAAP EPS of $0.12 significantly outperformed the expected loss of $0.84, while the operating loss of $1.48M was slightly narrower than the $1.6M consensus. The proposed merger with Noble Africa remains the primary catalyst, providing a critical $50M capital injection path to address substantial going concern doubts.